Avalo Therapeutics Inc.
AVTX | NASDAQ
$16.17
-$0.40 (-2.41%)
At close: Sep 21, 2026, 4:00 PM ET
$16.17
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Market Data
Market Cap $849.99M
Enterprise Value $449.71M
Beta 0.79
Average Volume 1.62M
Shares Outstanding (Diluted) 43.6M
Shares Change YoY 302.61%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US05338F3064
Price Performance
Price Change 1M -17.8%
Price Change 3M -9.3%
Price Change 6M 15.9%
Price Change YTD -5.0%
Price Change 1Y 38.2%
Price Change 3Y -43.4%
Price Change 5Y -99.8%
1M CAGR (ann.) -11.7%
1Y CAGR (ann.) 36.1%
5Y CAGR (ann.) -70.9%
All-Time CAGR -47.5%
Valuation
PE Ratio -3.41
Forward PE N/A
PEG Ratio 0.02
Forward PEG -0.86
PS Ratio 14,406.54
Forward PS 850.00
PB Ratio 1.89
P/FCF Ratio -12.81
P/Adj. FCF Ratio -10.25
P/OCF Ratio -10.64
EV/Sales 7,622.20
EV/EBIT -4.49
EV/EBITDA -4.50
EV/FCF -6.77
Earnings Yield -29.3%
FCF Yield -7.8%
Adj. FCF Yield -9.8%
Financial Health
Net Cash $400.28M
Total Debt $0
Cash & Short-Term Investments $400.28M
Total Assets $490.78M
Current Ratio 19.31
Quick Ratio 19.31
Debt / Equity Ratio 0.00
Debt / EBITDA -0.00
Debt / FCF -0.00
OCF / Debt N/A
Interest Coverage 0.00
Altman Z-Score 10.94
Piotroski F-Score 3
Margins & Profitability
Gross Profit Margin -16861.0%
Operating Profit Margin -154844.1%
EBITDA Margin -169552.5%
Net Profit Margin -170055.9%
FCF Margin -112505.1%
Adj. FCF Margin -140542.4%
SBC / Revenue 28037.3%
SBC Impact (per share) -24.9%
Returns
Return on Assets -20.4%
Return on Equity -58.0%
Return on Invested Capital -19.4%
Return on Capital Employed -19.4%
Return on Tangible Assets -20.9%
Historical Growth (CAGR)
Revenue CAGR 3Y -84.8%
Revenue CAGR 5Y -60.9%
Revenue CAGR 10Y -21.3%
EPS CAGR 3Y 150.0%
EPS CAGR 5Y 83.7%
EPS CAGR 10Y 14.4%
FCF CAGR 3Y -35.1%
FCF CAGR 5Y -8.1%
FCF CAGR 10Y -19.1%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 10
EPS Growth Next 3Y 7.4%
Revenue Growth Next 3Y 431.1%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) -$0.63
EPS Growth Est (next Q) -71.2%
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $45.13
Price Target Upside 179.1%
Cash Flow
Operating Cash Flow $-66.38M
Free Cash Flow $-66.38M
Adj. Free Cash Flow $-82.92M
FCF Per Share -$1.52
OCF Per Share -$1.52
OCF/S Ratio -112505.1%
Income Statement
Revenue $59K
Gross Profit $-9.95M
Operating Income $-91.36M
EBITDA $-100.04M
Net Income $-100.33M
EPS (Diluted) -$4.74
Revenue / Employee $1.79K
Profit / Employee $-3.04M
Employees 33
Add to Watchlist
Select watchlists to add or remove AVTX